Clinical review: Idiopathic pulmonary fibrosis-Past, present and future

Respiratory Medicine

Volumn 100, Issue 11, 2006, Pages 1871-1885

  Dempsey, Owen J ^a  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

Fibroblastic focus; Interstitial lung disease; Usual interstitial pneumonitis

Indexed keywords

ACETYLCYSTEINE; ANTIBIOTIC AGENT; AZATHIOPRINE; BOSENTAN; CORTICOSTEROID; CORTISONE; CYCLOPHOSPHAMIDE; DIGITALIS; DIURETIC AGENT; ETANERCEPT; GAMMA INTERFERON; ILOPROST; IMATINIB; MINOCYCLINE; OXYGEN; PIRFENIDONE; PREDNISOLONE; RAPAMYCIN; SILDENAFIL; ZILEUTON;

ARTICLE; CANCER; CLINICAL FEATURE; CLINICAL TRIAL; COCHRANE LIBRARY; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; DISEASE EXACERBATION; EMBASE; EPIDEMIOLOGICAL DATA; HISTORY; HISTORY OF MEDICINE; HUMAN; INCIDENCE; LUNG BIOPSY; LUNG FIBROSIS; LUNG TRANSPLANTATION; MEDICAL LITERATURE; MEDICAL RESEARCH; MEDLINE; MORTALITY; PATHOGENESIS; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS;

ADMINISTRATION, ORAL; ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; COMBINED MODALITY THERAPY; CORTISONE; HUMANS; PROGNOSIS; PULMONARY FIBROSIS;

EID: 33749329160     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2006.08.017     Document Type: Article

References (109)

1. Flint A. A treatise on the principles and practice of medicine (1868), Henry C. Lea, Philadelphia p. 193
2. Sharma O.P., and Chan K. Idiopathic interstitial pneumonitis/fibrosis: a historical note. Curr Opin Pulm Med 5 (1999) 275-277
3. Flaherty K.R., Travis W.D., Colby T.V., et al. Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med 164 (2001) 1722-1727
4. Gribbin J, Hubbard RB, Le Jeune I, Smith CJP, West J, Tata LJ. The incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 2006; in press.
5. Visscher D.W., and Myers J.L. Histologic spectrum of idiopathic interstitial pneumonias. Proc Am Thorac Soc 3 (2006) 322-329
6. American Thoracic Society (ATS)/European Respiratory Society (ERS) classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 165 (2002) 277-304
7. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International Consensus Statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 161 (2000) 646-664
8. Leslie K.O. Pathology of interstitial lung disease. Clin Chest Med 25 (2004) 657-703
9. Kondoh Y., Taniguchi H., Kawabata Y., Yokoi T., Suzuki K., and Takagi K. Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases. Chest 103 (1993) 1808-1812
10. Hamman L., and Rich A.R. Acute diffuse interstitial fibrosis of the lungs. Bull John Hopkins Hosp 74 (1944) 177-212
11. Noble P.W., and Homer R.J. Back to the future: historical perspective on the pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 33 (2005) 113-120
12. Richeldi L., Davies H.R., Ferrara G., and Franco F. Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 3 (2003) CD002880
13. Davies H.R., Richeldi L., and Walters E.H. Immunomodulatory agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 3 (2003) CD003134
14. Selman M., Thannickal V.J., Pardo A., Zisman D.A., Martinez F.J., and Lynch III J.P. Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches. Drugs 64 (2004) 405-430
15. Selman M., and Pardo A. Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers. Proc Am Thorac Soc 3 (2006) 364-372
16. Lama V.N., and Phan S.H. The extrapulmonary origin of fibroblasts:stem/ progenitor cells and beyond. Proc Am Thorac Soc 3 (2006) 373-376
17. Willis B.C., du Bois R.M., and Borok Z. Epithelial origin of myofibroblasts during fibrosis in the lung. Proc Am Thorac Soc 3 (2006) 377-382
18. Garantziotis S., Steele M.P., and Schwartz D.A. Pulmonary fibrosis: thinking outside of the lung. J Clin Invest 114 (2004) 319-321
19. Phillips R.J., Burdick M.D., Hong K., et al. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest 114 (2004) 438-446
20. Demedts M., Wells A.U., Anto J.M., et al. Interstitial lung diseases: an epidemiological overview. Eur Respir J Suppl 32 (2001) 2s-16s
21. Coultas D.B., Zumwalt R.E., Black W.C., and Sobonya R.E. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 150 (1994) 967-972
22. von Plessen C., Grinde O., and Gulsvik A. Incidence and prevalence of cryptogenic fibrosing alveolitis in a Norwegian community. Respir Med 97 (2003) 428-435
23. Johnston I.D., Prescott R.J., Chalmers J.C., and Rudd R.M. British Thoracic Society study of cryptogenic fibrosing alveolitis:current presentation and initial management. Thorax 52 (1997) 38-44
24. Hubbard R., Lewis S., Richards K., Johnston I., and Britton J. Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis. Lancet 347 (1996) 284-289
25. Baumgartner K.B., Samet J.M., Coultas D.B., et al. Occupational and environmental risk factors for idiopathic pulmonary fibrosis: a multicenter case-control study. Am J Epidemiol 152 (2000) 307-315
26. Hubbard R., Venn A., Smith C., Cooper M., Johnston I., and Britton J. Exposure to commonly prescribed drugs and the etiology of cryptogenic fibrosing alveolitis: a case-control study. Am J Respir Crit Care Med 157 (1998) 743-747
27. Tobin R.W., Pope II C.E., Pellegrini C.A., Edmond M.J., Sillery J., and Raghu G. Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 158 (1998) 1804-1808
28. Patti M.G., Tedesco P., Golden J., et al. Idiopathic pulmonary fibrosis: how often is it really idiopathic?. J Gastrointest Surg 9 (2005) 1053-1056
29. Raghu G., Freudenberger T.D., Yang S., et al. High prevalence of abnormal acid gastro-oesophageal relux in idiopathic pulmonary fibrosis. Eur Respir J 27 (2006) 136-142
30. Scott J., Johnston I., and Britton J. What causes cryptogenic fibrosing alveolitis? A case-control study of environmental exposure to dust. BMJ 301 (1990) 1015-1017
31. Hubbard R., Cooper M., Antoniak M., et al. Risk of cryptogenic fibrosing alveolitis in metal workers. Lancet 355 (2000) 466-467
32. Egan J.J., Woodcock A.A., and Stewart J.P. Viruses and idiopathic pulmonary fibrosis. Eur Respir J 10 (1997) 1433-1437
33. Egan J.J., Stewart J.P., Hasleton P.S., Arrand J.R., Carroll K.B., and Woodcock A.A. Epstein-Barr virus replication within pulmonary epithelial cells in cryptogenic fibrosing alveolitis. Thorax 50 (1995) 1234-1239
34. Marshall R.P., Puddicombe A., Cookson W.O., and Laurent G.J. Adult familial cryptogenic fibrosis alveolitis in the United Kingdom. Thorax 55 (2000) 143-146
35. Hodgson U., Laitinen T., and Tukiainen P. Nationwide prevalence of sporadic and familial idiopathic pulmonary fibrosis: evidence of founder effect among multiplex families in Finland. Thorax 57 (2002) 338-342
36. Steele M.P., Speer M.C., Loyd J.E., et al. Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med 172 (2005) 1146-1152
37. Whyte M., Hubbard R., Meliconi R., et al. Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factor-alpha gene polymorphisms. Am J Respir Crit Care Med 162 (2000) 755-758
38. Nogee L.M., Dunbar III A.E., Wert S.E., Askin F., Hamvas A., and Whitsett J.A. A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med 344 (2001) 573-579
39. Thomas A.Q., Lane K., Phillips III J., et al. Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred. Am J Respir Crit Care Med 165 (2002) 1322-1328
40. Thannickal V.J., and Wells A.U. Classification of interstitial pneumonias: what do gene expression profiles tell us?. Am J Respir Crit Care Med 173 (2006) 141-142
41. Kaminski N., and Rosas I.O. Gene expression profiling as a window into idiopathic pulmonary fibrosis pathogenesis: can we identify the right target genes?. Proc Am Thorac Soc 3 (2006) 339-344
42. Kim D.S., Park J.H., Park B.K., Lee J.S., Nicholson A.G., and Colby T. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J 27 (2006) 143-150
43. Martinez F.J., Safrin S., Weycker D., et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 142 (2005) 963-967
44. Panos R.J., Mortenson R.L., Niccoli S.A., and King Jr. T.E. Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med 88 (1990) 396-404
45. Walter N., Collard H.R., and King T.E. Current perspectives on the treatment of idiopathic pulmonary fibrosis. Proc Am Thorac Soc 3 (2006) 330-338
46. Akira M., Hamada H., Sakatani M., Kobayashi C., Nishioka M., and Yamamoto S. CT findings during phase of accelerated deterioration in patients with idiopathic pulmonary fibrosis. Am J Roentgenol 168 (1997) 79-83
47. Kubo H., Nakayama K., Yanai M., et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 128 (2005) 1475-1482
48. Saydain G., Islam A., Afessa B., Ryu J.H., Scott J.P., and Peters S.G. Outcome of patients with idiopathic pulmonary fibrosis admitted to the intensive care unit. Am J Respir Crit Care Med 166 (2002) 839-842
49. Nava S., and Rubini F. Lung and chest wall mechanics in ventilated patients with end stage idiopathic pulmonary fibrosis. Thorax 54 (1999) 390-395
50. Lok S.S. Interstitial lung disease clinics for the management of idiopathic pulmonary fibrosis: a potential advantage to patients. J Heart Lung Transplant 18 (1999) 884-890
51. Flaherty K.R., King Jr. T.E., Raghu G., et al. Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?. Am J Respir Crit Care Med 170 (2004) 904-910
52. Epler G.R., McLoud T.C., Gaensler E.A., Mikus J.P., and Carrington C.B. Normal chest roentgenograms in chronic diffuse infiltrative lung disease. N Engl J Med 298 (1978) 934-939
53. Lynch D.A., Travis W.D., Muller N.L., et al. Idiopathic interstitial pneumonias: CT features. Radiology 236 (2005) 10-21
54. Aziz Z.A., Wells A.U., Hansell D.M., et al. HRCT diagnosis of diffuse parenchymal lung disease: inter-observer variation. Thorax 59 (2004) 506-511
55. Wiggins J., Strickland B., and Turner-Warwick M. Combined cryptogenic fibrosing alveolitis and emphysema: the value of high resolution computed tomography in assessment. Respir Med 84 (1990) 365-369
56. Egan J.J., Martinez F.J., Wells A.U., and Williams T. Lung function estimates in idiopathic pulmonary fibrosis: the potential for a simple classification. Thorax 60 (2005) 270-273
57. British Thoracic Society. The diagnosis, assessment and treatment of diffuse parenchymal lung disease in adults. Thorax 54 Suppl. 1 (1999) S1-S14
58. Tzouvelekis A., Kouliatsis G., Anevlavis S., and Bouros D. Serum biomarkers in interstitial lung diseases. Respir Res 6 (2005) 78
59. Yokoyama A., Kohno N., Hamada H., et al. Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 158 (1998) 1680-1684
60. Ohnishi H., Yokoyama A., Kondo K., et al. Am J Respir Crit Care Med 165 (2002) 378-381
61. Halkos M.E., Gal A.A., Kerendi F., Miller D.L., and Miller Jr. J.I. Role of thoracic surgeons in the diagnosis of idiopathic interstitial lung disease. Ann Thorac Surg 79 (2005) 2172-2179
62. Rocco G., Khalil M., and Jutley R. Uniportal video-assisted thoracoscopic surgery wedge lung biopsy in the diagnosis of interstitial lung diseases. J Thorac Cardiovasc Surg 129 (2005) 947-948
63. Hunninghake G.W., Zimmerman M.B., Schwartz D.A., et al. Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 164 (2001) 193-196
64. Lettieri C.J., Veerappan G.R., Parker J.M., et al. Discordance between general and pulmonary pathologists in the diagnosis of interstitial lung disease. Respir Med 99 (2005) 1425-1430
65. Lettieri C.J., Veerappan G.R., Helman D.L., Mulligan C.R., and Shorr A.F. Outcomes and safety of surgical lung biopsy for interstitial lung disease. Chest 127 (2005) 1600-1605
66. Kondoh Y, Taniguchi H, Kitaichi M, et al. Acute exacerbation of interstitial pneumonia following surgical lung biopsy. Respir Med 2006; in press.
67. Bjoraker J.A., Ryu J.H., Edwin M.K., et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 157 (1998) 199-203
68. Nicholson A.G., Colby T.V., du Bois R.M., Hansell D.M., and Wells A.U. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 162 (2000) 2213-2217
69. Daniil Z.D., Gilchrist F.C., Nicholson A.G., et al. A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 160 (1999) 899-905
70. Douglas W.W., Ryu J.H., Swensen S.J., et al. Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis: a randomized prospective study. Am J Respir Crit Care Med 158 (1998) 220-225
71. King Jr. T.E., Tooze J.A., Schwarz M.I., Brown K.R., and Cherniack R.M. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 164 (2001) 1171-1181
72. Wells A.U., Desai S.R., Rubens M.B., et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med 167 (2003) 962-969
73. Latsi P.I., du Bois R.M., Nicholson A.G., et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 168 (2003) 531-537
74. Collard H.R., King Jr. T.E., Bartelson B.B., Vourlekis J.S., Schwarz M.I., and Brown K.K. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 168 (2003) 538-542
75. Flaherty K.R., Thwaite E., Kazerooni E.A., et al. Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax 58 (2003) 143-148
76. Noble P.W., and Morris D.G. Time will tell: predicting survival in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 168 (2003) 510-511
77. Jegal Y., Kim D.S., Shim T.S., et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 171 (2005) 639-644
78. Benson M.K., and Hughes D.T. Serial pulmonary function tests in fibrosing alveolitis. Br J Dis Chest 66 (1972) 33-44
79. Flaherty KR, Andrei AC, Murray S, et al. Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six minute hallwalk. Am J Respir Crit Care Med 2006; in press.
80. Lettieri CJ, Nathan SD, Browning RF, Barnett SD, Ahmad S, Shorr AF. The distance-saturation product predicts mortality in idiopathic pulmonary fibrosis. Resp Med 2006; in press
81. Strange C., and Highland K.B. Pulmonary hypertension in interstitial lung disease. Curr Opin Pul Med 11 (2005) 452-455
82. Nadrous H.F., Pellikka P.A., Krowka M.J., et al. The impact of pulmonary hypertension on survival in patients with idiopathic pulmonary fibrosis. Chest 128 (2005) 616S-617S
83. Orens J.B., Estenne M., Arcasoy S., et al. International guidelines for the selection of lung transplant recipients: 2006 update-a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 25 (2006) 745-755
84. British Thoracic Society Working Group on Home Oxygen Services. Clinical component for the home oxygen service in England and Wales. Accessed 25 March 2006 〈http://www.brit-thoracic.org.uk〉.
85. Harris-Eze A.O., Sridhar G., Clemens R.E., Gallagher C.G., and Marciniuk D.D. Oxygen improves maximal exercise performance in interstitial lung disease. Am J Respir Crit Care Med 150 (1994) 1616-1622
86. British Thoracic Society Standards of Care Subcommittee on Pulmonary Rehabilitation. Pulmonary rehabilitation. Thorax 56 (2001) 827-834
87. Caplan-Shaw C.E., Arcasoy S.M., Shane E., et al. Osteoporosis in diffuse parenchymal lung disease. Chest 129 (2006) 140-146
88. American College of Rheumatology. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 44 (2001) 1496-1503
89. Swigris J.J., Kuschner W.G., Jacobs S.S., Wilson S.R., and Gould M.K. Health-related quality of life in patients with idiopathic pulmonary fibrosis: a systematic review. Thorax 60 (2005) 588-594
90. Mapel D.W., Samet J.M., and Coultas D.B. Corticosteroids and the treatment of idiopathic pulmonary fibrosis. Past, present, and future. Chest 110 (1996) 1058-1067
91. Whitfield A.G.W. Steroid therapy in pulmonary fibroses. Brit J Dis Chest 53 (1959) 28-40
92. Flaherty K.R., Toews G.B., Lynch III J.P., et al. Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival. Am J Med 110 (2001) 278-282
93. Raghu G., Depaso W.J., Cain K., et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 144 (1991) 291-296
94. Ziesche R., Hofbauer E., Wittmann K., Petkov V., and Block L.H. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 341 (1999) 1264-1269
95. Johnson M.A., Kwan S., Snell N.J., Nunn A.J., Darbyshire J.H., and Turner-Warwick M. Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax 44 (1989) 280-288
96. Winterbauer R.H. The treatment of idiopathic pulmonary fibrosis. Chest 100 (1991) 233-235
97. Raghu G., Brown K.K., Bradford W.Z., et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 350 (2004) 125-133
98. Azuma A., Nukiwa T., Tsuboi E., et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 171 (2005) 1040-1047
99. Demedts M., Behr J., Buhl R., et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. New Engl J Med 353 (2005) 2229-2242
100. Raghu G., Lasky J.A., Costabel U., et al. A randomized placebo controlled trial assessing the efficacy and safety of etanercept in patients with idiopathic pulmonary fibrosis. Chest 128 (2005) 496S
101. King T.E., Behr J., Brown K.K., du Bois R.M., and Raghu G. Bosentan use in idiopathic pulmonary fibrosis (IPF): results of the placebo controlled BUILD-1 study. Am J Respir Crit Care Med 3 (2006) A524
102. Humbert M., Sitbon O., and Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 351 (2004) 1425-1436
103. Daniels C.E., Wilkes M.C., Edens M., et al. Imatinib mesylate inhibits the profibrogenc activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 114 (2004) 1308-1316
104. Gao F., Myllarniemi M., Tobolewski J.M., Kinnula V., and Oury T.D. Gleevec, hope for IPF?. Am J Respir Crit Care Med 3 (2006) A524
105. Sehgal S.N. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action, immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 39 (2006) 484-489
106. Simler N.R., Howell D.C., Marshall R.P., et al. The rapamycin analogue SDZ RAD attenuates bleomycin-induced pulmonary fibrosis in rats. Eur Respir J 19 (2002) 1124-1127
107. Bouros D., and Antoniou K.M. Current and future therapeutic approaches in idiopathic pulmonary fibrosis. Eur Respir J 26 (2005) 693-702
108. Ghofrani H.A., Wiedemann R., Rose F., et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 360 (2002) 895-900
109. Peters-Golden M., Bailie M., Marshall T., et al. Protection from pulmonary fibrosis in leukotriene-deficient mice. Am J Respir Crit Care Med 165 (2002) 229-235